日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human.

CD168 可识别小鼠和人类胰岛增殖细胞。

Yuan Shubo, Li Jiafu, Shao Min, Bao Haili, Geng Ajun, Yang Jialin, Tao Yu, Chen Xinyi, Xiao Tianxiong, Liu Chunye, Xie Zhiyao, Song Wenqian, Yu Qing Cissy, Fu Hongxing, Han Xu, He Taochen, Wang Wenquan, Chen Jianfeng, Yan Sheng, Song Shaohua, Liu Liang, Zeng Yi Arial

Noncoding RNA Terc-53 and hyaluronan receptor Hmmr regulate ageing in mice

非编码RNA Terc-53和透明质酸受体Hmmr调节小鼠衰老

Sipeng Wu, Yiqi Cai, Lixiao Zhang, Xiang Li, Xu Liu, Guangkeng Zhou, Hongdi Luo, Renjian Li, Yujia Huo, Zhirong Zhang, Siyi Chen, Jinliang Huang, Jiahao Shi, Shanwei Ding, Zhe Sun, Zizhuo Zhou, Pengcheng Wang, Geng Wang

Response Regulator CD1688 Is a Negative Modulator of Sporulation in Clostridioides difficile

反应调节因子 CD1688 是艰难梭菌孢子形成的负调控因子

Kempher, Megan L; Morris, Savannah C; Shadid, Tyler M; Menon, Smita K; Ballard, Jimmy D; West, Ann H

Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias - assessment of clinical outcome, post induction, end of treatment and minimal residual disease

透明质酸介导的运动受体(CD168)在急性儿童白血病中的预后意义——临床结局评估、诱导治疗后、治疗结束时及微小残留病

Shalini, Chinnathambi Narayanan Sai; Suman, Febe Renjitha; Jacob, Jerusha Samuela; Rajendran, Rithika; Scott, Julius Xavier; Latha, Magadha Sneha

Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors

用于治疗 RHAMM (CD168) 过表达癌症(包括原发性和转移性肿瘤)的氧化还原响应型透明质酸纳米凝胶

Yang, Chenchen; Li, Cheng; Zhang, Peng; Wu, Wei; Jiang, Xiqun

Expression patterns of CD168 correlate with the stage and grade of squamous cell carcinoma of head and neck

CD168的表达模式与头颈部鳞状细胞癌的分期和分级相关

Jöhrens, Korinna; Anagnostopoulos, Ioannis; Dommerich, Steffen; Raguse, Jan Dirk; Szczepek, Agnieszka J; Klauschen, Frederick; Stölzel, Katharina

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia

RHAMM/HMMR (CD168) 不是急性髓系白血病免疫治疗的理想靶抗原。

Snauwaert, Sylvia; Vanhee, Stijn; Goetgeluk, Glenn; Verstichel, Greet; Van Caeneghem, Yasmine; Velghe, Imke; Philippé, Jan; Berneman, Zwi N; Plum, Jean; Taghon, Tom; Leclercq, Georges; Thielemans, Kris; Kerre, Tessa; Vandekerckhove, Bart

RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease

RHAMM (CD168) 在蛋白水平上过度表达,可能构成晚期前列腺癌中的一种免疫原性抗原。

Gust, Kilian M; Hofer, Matthias D; Perner, Sven R; Kim, Robert; Chinnaiyan, Arul M; Varambally, Sooryanarayana; Moller, Peter; Rinnab, Ludwig; Rubin, Mark A; Greiner, Jochen; Schmitt, Michael; Kuefer, Rainer; Ringhoffer, Mark